News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Date Title Source
2022-06-14 8:58:16 am Adial gets US patent linked to AD04, diagnostic test for alcohol/opioid use disorder SeekingAlpha
Jun-14-22 10:48AM Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Companys Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence GlobeNewswire
May-19-22 09:25AM Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovates Adenosine Compounds as Potential Treatments for Diabetes and NASH GlobeNewswire
May-16-22 09:25AM Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results GlobeNewswire
May-05-22 04:05PM Maravai LifeSciences Reports First Quarter 2022 Financial Results GlobeNewswire
May-04-22 09:15AM Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovates Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders GlobeNewswire
Apr-06-22 07:47AM 5 Winning Stocks Backed by the Overlooked Rising P/E Strategy Zacks
Mar-22-22 09:15AM Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th GlobeNewswire
Feb-24-22 09:15AM Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder GlobeNewswire
Feb-16-22 09:26AM Adial Pharmaceuticals Announces Closing of $10 Million Financing GlobeNewswire
Feb-11-22 09:00AM Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering GlobeNewswire
Feb-09-22 09:25AM Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovates PNV-5032 as a Potential Treatment for Asthma GlobeNewswire
Jan-24-22 09:25AM Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04 GlobeNewswire
Jan-12-22 09:40AM Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year? Zacks
Jan-10-22 09:03AM Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference GlobeNewswire
Dec-22-21 09:25AM Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share GlobeNewswire
Dec-08-21 09:25AM Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer GlobeNewswire
Nov-29-21 09:00AM Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer GlobeNewswire
Nov-17-21 09:42AM REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments GlobeNewswire
Nov-10-21 09:26AM Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options GlobeNewswire
Nov-09-21 09:15AM Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments GlobeNewswire
Nov-03-21 09:10AM Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors GlobeNewswire
Oct-21-21 01:06PM Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate Benzinga
Oct-21-21 10:13AM Adial Announces Positive Pre-Clinical Data for Purnovates PNV-5030 as a Drug Candidate for the Treatment of Pain GlobeNewswire
Oct-21-21 09:45AM Adial Announces Positive Pre-Clinical Data for Purnovates PNV-5030 as Drug Candidate for the Treatment of Pain GlobeNewswire
Oct-18-21 09:30AM Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021 GlobeNewswire
Oct-05-21 09:25AM Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021 ACCESSWIRE
Oct-04-21 04:30PM 36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021 ACCESSWIRE
Sep-30-21 09:25AM Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period Trial Completion Anticipated Q1 2022 GlobeNewswire
Sep-28-21 09:49AM Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing GlobeNewswire
Sep-15-21 10:07AM Adial CEO William Stilley Invited to Participate in Maxim Groups Virtual Panel Series Conference: Disruptors in the Mental Health Space GlobeNewswire
Sep-13-21 09:30AM Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors GlobeNewswire
Sep-07-21 09:00AM Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-31-21 09:30AM Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder GlobeNewswire
Aug-20-21 10:45AM Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder GlobeNewswire
Aug-20-21 09:40AM Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments GlobeNewswire
Aug-12-21 02:50PM Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments GlobeNewswire
Aug-10-21 09:30AM Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04 GlobeNewswire
Aug-05-21 10:12AM Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market GlobeNewswire
Jul-29-21 09:30AM Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com GlobeNewswire
Jul-14-21 02:00PM Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform GlobeNewswire
Jul-07-21 10:11AM Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share GlobeNewswire
Jul-06-21 09:25AM The Phase 3 ONWARD Trial Meets its Screening Target and Nears Enrollment Completion GlobeNewswire
Jul-06-21 08:30AM Former member of the National Advisory Council on Drug Abuse (NACDA) and National Institute on Drug Abuse (NIDA) Joins Ehave, Inc; Ehave Appoints Psychopharmacologist, Board-Certified Psychiatrist, And Licensed Physician, Bankole Johnson To Its Medical Advisory Board GlobeNewswire
Jun-28-21 09:45AM Adial Joins Russell Microcap® Index GlobeNewswire
Jun-25-21 09:02AM FDA Denies Adial Pharma's Fast Track Request For AD04 in Alcohol Use Disorder Benzinga
Jun-24-21 05:07PM Adial Pharmaceuticals Provides Regulatory and Development Update GlobeNewswire
Jun-22-21 09:55AM Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test GlobeNewswire
Jun-07-21 09:30AM Adial Pharmaceuticals Comments on Article in The Atlantic, Highlighting the Second Pandemic of Addiction GlobeNewswire
Jun-03-21 09:54AM Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share GlobeNewswire
May-18-21 01:19PM Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder GlobeNewswire
Apr-07-21 11:09AM Adial Pharma Seeks To Treat The Pandemic Of Addiction Benzinga
Mar-23-21 09:00AM Adial Pharmaceuticals to Participate at the Benzinga Biotech Small Cap Conference on March 24th Newsfile
Mar-17-21 10:00AM Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel GlobeNewswire
Mar-15-21 09:30AM Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share GlobeNewswire
Feb-26-21 03:05PM Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion GlobeNewswire
Feb-26-21 11:20AM Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants GlobeNewswire
Feb-25-21 09:30AM Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD Phase 3 Trial GlobeNewswire
Feb-23-21 01:00PM Adial to File Fast Track Application for AD04 with the FDA GlobeNewswire
Jan-26-21 10:15AM Adial Pharmaceuticals Closes Acquisition of Purnovate ACCESSWIRE
Jan-11-21 11:00AM Adial Pharmaceuticals to Present at 23rd Annual ICR Conference ACCESSWIRE
Jan-11-21 09:50AM Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder ACCESSWIRE
Dec-17-20 09:45AM Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder ACCESSWIRE
Dec-15-20 09:30AM Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory ACCESSWIRE
Dec-10-20 12:10PM Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments ACCESSWIRE
Dec-10-20 09:30AM Adial Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment of Addiction ACCESSWIRE
Dec-09-20 11:25AM Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley ACCESSWIRE
Dec-04-20 09:30AM Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured in Follow-up TV News Story ACCESSWIRE
Nov-25-20 12:20PM Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured on Multiple Television News Outlets ACCESSWIRE
Nov-25-20 09:30AM Adial Pharmaceuticals Enters into Common Stock Purchase Agreement with Keystone Capital Partners to Support Strategic Opportunities and Future Growth Initiatives ACCESSWIRE
Nov-16-20 05:33AM We Think Adial Pharmaceuticals (NASDAQ:ADIL) Needs To Drive Business Growth Carefully Simply Wall St.
Nov-03-20 09:50AM Adial Pharmaceuticals Provides Update on its ONWARD(TM) Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder ACCESSWIRE
Oct-22-20 09:30AM Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep(R) Point-of-Care Covid-19 Antibody Tests ACCESSWIRE
Oct-22-20 08:30AM Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices GlobeNewswire
Oct-22-20 08:30AM Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices ACCESSWIRE
Oct-21-20 09:30AM Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder ACCESSWIRE
Sep-30-20 09:25AM Adial Pharmaceuticals Announces Sale of 10,000 COVID-19 Antibody Rapid Test Devices ACCESSWIRE
Sep-29-20 09:30AM Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples ACCESSWIRE
Sep-25-20 10:00AM Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA ACCESSWIRE
Sep-22-20 09:30AM Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales ACCESSWIRE
Sep-09-20 09:00AM Adial Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th ACCESSWIRE
Sep-01-20 07:22PM Adial Pharmaceuticals to Present at The LD Micro 500 Virtual Conference on September 2nd ACCESSWIRE
Aug-31-20 05:00PM LD Micro - 360 Companies Set to Present this Week ACCESSWIRE
Aug-06-20 09:30AM Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits ACCESSWIRE
Aug-05-20 09:00AM LD Micro Announces Preliminary List of Presenters for the LD 500 ACCESSWIRE
Jul-28-20 09:30AM Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call ACCESSWIRE
Jul-22-20 09:45AM Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder ACCESSWIRE
Jul-06-20 08:15AM Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia ACCESSWIRE
Jun-25-20 09:30AM Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland ACCESSWIRE
Jun-17-20 09:55AM Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia ACCESSWIRE
Jun-15-20 09:30AM Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering ACCESSWIRE
Jun-11-20 11:35AM Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland ACCESSWIRE
Jun-10-20 10:06AM Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits ACCESSWIRE
Jun-09-20 09:15AM Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market ACCESSWIRE
Jun-08-20 09:30AM Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests ACCESSWIRE
May-28-20 09:30AM Adial Pharmaceuticals Appoints Dr. Jack Reich to Board of Directors ACCESSWIRE
May-04-20 10:15AM Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress ACCESSWIRE
Apr-23-20 08:45AM Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility ACCESSWIRE
Apr-16-20 10:17AM Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial ACCESSWIRE
Apr-15-20 09:45AM Adial Pharmaceuticals Issued Second Patent Covering AD04 as a Treatment for Opioid Use Disorder ACCESSWIRE
Apr-09-20 09:30AM Adial Pharmaceuticals Provides Update on ONWARD(TM) Phase 3 Pivotal Trial ACCESSWIRE